Cue Biopharma Inc
CUE0.736USD
+0.003+0.42%
交易中 （美东）报价延迟15分钟
56.30M总市值
亏损市盈率 TTM
关于 Cue Biopharma Inc 公司
Cue Biopharma, Inc. 是一家临床阶段的生物制药公司，正在开发一种新型治疗生物制剂，以选择性调节疾病特异性 T 细胞。该公司的平台 Immuno-STAT（T 细胞的选择性靶向和改变）和生物制剂旨在通过选择性调节疾病特异性 T 细胞来发挥人体内在免疫系统的治疗潜力，而不会产生广泛的全身免疫调节的不良影响。其两种肿瘤药物候选产品 CUE-101 和 CUE-102 是基于白细胞介素 2 (IL-2) 的 CUE-100 系列的典型项目，代表了在美国和西欧地区流行的 HLA-A02 等位基因。CUE-101 HLA-A02 被设计用于治疗人乳头瘤病毒阳性的头颈部鳞状细胞癌 (HNSCC)。 CUE-102 HLA-A02，针对 Wilms 肿瘤 1 蛋白，这是一种已知在 20 多种不同癌症中过度表达的癌胚抗原。
Cue Biopharma Inc简介
公司代码CUE
公司名称Cue Biopharma Inc
上市日期Jan 02, 2018
CEOMr. Daniel R. (Dan) Passeri, J.D.
员工数量41
证券类型Ordinary Share
年结日Jan 02
公司地址40 Guest Street
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02135
电话16179492680
网址https://www.cuebiopharma.com/
公司代码CUE
上市日期Jan 02, 2018
CEOMr. Daniel R. (Dan) Passeri, J.D.
Cue Biopharma Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
28.00K
--
Mr. Patrick Verheyen
Mr. Patrick Verheyen
Independent Director
Independent Director
8.17K
--
Dr. Usman (Oz) Azam, M.D.
Dr. Usman (Oz) Azam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jill Broadfoot
Mr. Jill Broadfoot
Director
Director
--
--
Dr. Daniel G. (Dan) Baker, M.D.
Dr. Daniel G. (Dan) Baker, M.D.
Interim Chief Development Officer
Interim Chief Development Officer
--
--
Mr. Pasha Sarraf
Mr. Pasha Sarraf
Independent Director
Independent Director
--
--
Ms. Lucinda Warren
Ms. Lucinda Warren
Chief Business officer
Chief Business officer
--
--
Mr. Colin G. Sandercock, J.D.
Mr. Colin G. Sandercock, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Dr. Peter A. Kiener, Ph.D.
Dr. Peter A. Kiener, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matteo Levisetti, M.D.
Mr. Matteo Levisetti, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
28.00K
--
Mr. Patrick Verheyen
Mr. Patrick Verheyen
Independent Director
Independent Director
8.17K
--
Dr. Usman (Oz) Azam, M.D.
Dr. Usman (Oz) Azam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jill Broadfoot
Mr. Jill Broadfoot
Director
Director
--
--
Dr. Daniel G. (Dan) Baker, M.D.
Dr. Daniel G. (Dan) Baker, M.D.
Interim Chief Development Officer
Interim Chief Development Officer
--
--
Mr. Pasha Sarraf
Mr. Pasha Sarraf
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
Bleichroeder LP
8.87%
Catalytic Wealth RIA, LLC
4.34%
The Vanguard Group, Inc.
4.15%
Geode Capital Management, L.L.C.
0.90%
Robertson Stephens Wealth Management, LLC
0.62%
其他
81.12%
持股股东
持股股东
占比
Bleichroeder LP
8.87%
Catalytic Wealth RIA, LLC
4.34%
The Vanguard Group, Inc.
4.15%
Geode Capital Management, L.L.C.
0.90%
Robertson Stephens Wealth Management, LLC
0.62%
其他
81.12%
股东类型
持股股东
占比
Investment Advisor
19.92%
Investment Advisor/Hedge Fund
1.91%
Research Firm
0.52%
Individual Investor
0.35%
Hedge Fund
0.17%
Pension Fund
0.04%
Venture Capital
0.03%
其他
77.06%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
167
17.36M
22.60%
+933.19K
2025Q2
179
14.76M
19.58%
-2.35M
2025Q1
184
11.80M
15.77%
-6.74M
2024Q4
187
12.14M
19.16%
-6.53M
2024Q3
186
14.27M
23.69%
-3.80M
2024Q2
196
14.21M
29.21%
-5.75M
2024Q1
221
17.52M
36.59%
-3.12M
2023Q4
227
16.02M
35.92%
-2.73M
2023Q3
232
16.26M
36.70%
-4.68M
2023Q2
232
16.06M
37.54%
-1.73M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bleichroeder LP
6.82M
8.87%
+1.82M
+36.46%
Jun 30, 2025
Catalytic Wealth RIA, LLC
3.33M
4.34%
+3.33M
--
Jun 30, 2025
The Vanguard Group, Inc.
3.19M
4.15%
+871.48K
+37.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
692.17K
0.9%
-1.72K
-0.25%
Jun 30, 2025
Robertson Stephens Wealth Management, LLC
478.50K
0.62%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
446.59K
0.58%
-113.22K
-20.22%
Jun 30, 2025
BofA Global Research (US)
324.58K
0.42%
+233.00
+0.07%
Jun 30, 2025
UBS Financial Services, Inc.
292.58K
0.38%
+231.27K
+377.20%
Jun 30, 2025
Advisory Research, Inc.
257.23K
0.33%
--
--
Jun 30, 2025
1919 Investment Counsel, LLC
196.56K
0.26%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 7 小时前
更新时间: 7 小时前
机构名称
占比
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
查看更多
iShares Russell 2000 Growth ETF
占比0%
Global X Russell 2000 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Russell 2000 ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
ProShares UltraPro Russell2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
